Transcarent CEO Glen Tullman spent much of 2024 hinting that his health benefits upstart might be shopping around for acquisitions, and just over a week into the new year, he’s making good on it: Transcarent on Wednesday announced it will buy Accolade, another benefits company, for $621 million — more than double Accolade’s value on the stock market the day before.
